Maheshwari Anshul, the Chief Operating and Financial Officer of SI-BONE, Inc., has reported the sale of 3,738 shares of the company's common stock. This transaction, which took place on October 29, 2026, is significant as it underscores the ongoing trading activities of key executives within the surgical and medical instruments industry.

The sale was executed under a 10b5-1 trading plan, a strategy that allows executives to set up a predetermined schedule for stock transactions, thereby reducing the risk of insider trading allegations. Anshul's decision to sell shares at a price of $22.50 each reflects a structured approach to managing his stock holdings.

Background

SI-BONE, Inc., identified by the Central Index Key 0001459839, operates within the surgical and medical instruments sector, classified under the SIC code 3841. The company is incorporated in Delaware and has its fiscal year ending on December 31. SI-BONE has been actively involved in developing innovative solutions for spinal surgery, contributing to advancements in the medical field.

What the Filing Says

The recent filing, accession number 0001853089-26-000012, indicates that Anshul sold 3,738 shares on October 29, 2026. Following this transaction, he retains ownership of 214,497 shares, which includes 160,823 shares that are issuable upon the settlement of restricted stock units. The filing specifies, "The sale reported on this Form 4 was effected pursuant to a 10b5-1 trading plan dated December 17, 2025." This structured plan allows for the sale of shares without the risk of insider trading concerns.

Impact

This transaction may affect various stakeholders, including investors and analysts monitoring SI-BONE's stock performance. Anshul's role as an officer at SI-BONE positions him as a key figure in the company's financial strategies, and his stock transactions can influence market perceptions of the company's stability and growth potential.

What's Next

The filing does not say what happens next.